Incidence and risk of post-COVID-19 thromboembolic disease and the impact of aspirin prescription; nationwide observational cohort at the US Department of Veteran Affairs.
Anna D WareZachary P VeigulisPeter J HooverTerri L BlumkeGeorge N IoannouEdward J BoykoThomas F OsbornePublished in: PloS one (2024)
Findings demonstrated that preexisting aspirin prescription prior to COVID-19 diagnosis was associated with significantly decreased risk of venous thromboembolism and pulmonary embolism but increased risk of acute arterial disease. The risk of arterial disease may be associated with increased COVID-19 prothrombotic effects superimposed on preexisting chronic cardiovascular disease for which aspirin was already prescribed. Prospective clinical trials may help to further assess the efficacy of aspirin use prior to COVID-19 diagnosis for the prevention of post-COVID-19 thromboembolic disorders.
Keyphrases
- coronavirus disease
- sars cov
- pulmonary embolism
- low dose
- cardiovascular disease
- clinical trial
- venous thromboembolism
- cardiovascular events
- antiplatelet therapy
- respiratory syndrome coronavirus
- type diabetes
- risk factors
- atrial fibrillation
- randomized controlled trial
- drug induced
- intensive care unit
- anti inflammatory drugs
- tertiary care